Effects of Antiangiogenic Agent Bevacizumab on Over Cancer Cell Culture (Ovcar-3) Alone and Combined with Classic Chemotherapeutics

Abstract

Hulusi Goktug Gurer, Ceren Yildiz Eren*, Ozlem Ozgür Gursoy, Ayşe Tansu Koparal, Sabit Sinan Ozalp

Background: Cancer is an important problem that has serious effects on the quality of life. Despite advances in diagnosis, it still affects millions of people. Ovarian cancer is the most common cause of gynecological cancer deaths; it has a very important place in gynecological oncology. Combination therapy is a treatment method that combines more than one agent used in treatment. Today it is one of the most important weapons in cancer treatment. Methods: In this study, the aim was to examine the sole and combined effects of classical chemotherapeutics and Bevacizumab on Ovcar-3 cells in vitro. Results: To determine the effects of classical chemotherapeutics, and Bevacizumab on Ovcar-3 cells, MTT, DAPI staining, caspase-3 and real-time PCR analyses was performed. In the light of the data obtained from the MTT results, it was determined that bevacizumab did not have any effect on ovcar-3 cells, so DAPI staining and caspase-3 analyses were not conducted with this substance. It was observed that the combination of paclitaxel 2.5 nm+carboplatin 100 µm caused a decrease on IRS, COX-2 and VEGF gene levels. Bevacizumab was not included in the analysis as it was found to have no effect on ovcar-3 cells. Conclusion: In this study, classical chemotherapeutics sole and in combination showed significant anticancer effects in MTT, DAPI Staining, Caspase-3 and Real-Time PCR analyses in Ovcar-3 cancer cell lines. However, the same effect was not observed with Bevacizumab and this is different from some results in the literature. Researching this subject with new studies will contribute to the literature.